

## REMARKS

Claims 1-50 stand rejected in the Office Action mailed 13 March 2001 (the "Office Action") pursuant to a statutory type (35 U.S.C. §101) double patenting rejection. Applicant respectfully requests reconsideration or further examination pursuant to 37 C.F.R. §1.111.

Claims 1-50 have been cancelled. Claims 51-100 have been added to claim how insulin action values  $F_k(t_d)$  and future glucose values  $G(t_j)$  are determined. Formulas programmed into the microprocessor to determine each of these values are claimed. These formulas define methods and systems of the invention for the to accurately predicting future glucose values of a diabetic user under a variety of available dietary and insulin regimes.

The cancellation of Claims 1-50 obviate the statutory double patenting rejection. Applicant requests that pending claims 51-100 be passed to allowance.

If the examiner has questions, the examiner is invited to contact the applicant's attorney listed below.

Respectfully submitted,

BLACK LOWE & GRAHAM<sup>PLLC</sup>



Mark L. Crohn  
Registration No. 40,573  
Direct Dial: 206.287.0099



BLACK LOWE & GRAHAM<sup>PLLC</sup>